TP53 and melanoma: Although TP53 mutations and MDM2 amplifications in human melanoma are less common [23–25, 45, 54, 56], 16/37 (43%) of the cases in our cohort of canine melanoma bore focal amplifications of MDM2 or truncating TP53 mutations (Fig 1C).